A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer

Inhibitory Effect of CAPE and Kaempferol in Colon Cancer Cell Lines—Possible Implications in New Therapeutic Strategies

(2019) Liviuta Budisan et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation

(2019) Francesco Marampon et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Autophagy-induced senescence is regulated by p38α signaling

(2019) Konstantin Slobodnyuk et al.   Cell Death & Disease

The Function of Non-Coding RNAs in Lung Cancer Tumorigenesis

(2019) Cornelia Braicu et al.   Cancers

Role of Key Micronutrients from Nutrigenetic and Nutrigenomic Perspectives in Cancer Prevention

(2019) Alexandra Iulia Irimie et al.   Medicina-Lithuania

FGF5 promotes osteosarcoma cells proliferation via activating MAPK signaling pathway

(2019) Dunxin Han et al.   Cancer Management and Research

Natural products with anti-aging potential: Affected targets and molecular mechanisms

(2018) Cristina-Sorina Cătană et al.   BIOTECHNOLOGY ADVANCES

Oncogenic Signaling Pathways in The Cancer Genome Atlas

(2018) Francisco Sanchez-Vega et al.   CELL

PTEN is indispensable for cells to respond to MAPK inhibitors in myeloid leukemia

(2018) Jingliao Zhang et al.   CELLULAR SIGNALLING

Effects of PTEN Loss and Activated KRAS Overexpression on Mechanical Properties of Breast Epithelial Cells

(2018) Will Linthicum et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

NSC 95397 Suppresses Proliferation and Induces Apoptosis in Colon Cancer Cells through MKP-1 and the ERK1/2 Pathway

(2018) Navneet Dubey et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models

(2018) Anais Del Curatolo et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

EGFR-TKIs resistance via EGFR-independent signaling pathways

(2018) Qian Liu et al.   Molecular Cancer

RAS–MAPK Reactivation Facilitates Acquired Resistance inFGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade

(2018) Bruno Bockorny et al.   MOLECULAR CANCER THERAPEUTICS

Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers

(2018) Hiroshi Kotani et al.   ONCOGENE

Toosendanin, a natural product, inhibited TGF-β1-induced epithelial-mesenchymal transition through ERK/Snail pathway

(2018) Weiwei Luo et al.   PHYTOTHERAPY RESEARCH

The Role of Autophagy in the Resistance to BRAF Inhibition in BRAF-Mutated Melanoma

(2018) Xiao Liu et al.   Targeted Oncology

Keeping Tumors Out of the MAPK Fitness Zone

(2018) David F. Stern   Cancer Discovery

Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy

(2018) Feifei Liu et al.   Acta Pharmaceutica Sinica B

Insights of Crosstalk between p53 Protein and the MKK3/MKK6/p38 MAPK Signaling Pathway in Cancer

(2018) Lorenzo Stramucci et al.   Cancers

mTOR Cross-Talk in Cancer and Potential for Combination Therapy

(2018) Fabiana Conciatori et al.   Cancers

Enterolactone modulates the ERK/NF-κB/Snail signaling pathway in triple-negative breast cancer cell line MDA-MB-231 to revert the TGF-β-induced epithelial–mesenchymal transition

(2018) V. Mali Aniket et al.   Cancer Biology & Medicine

The role of pseudophosphatases as signaling regulators

(2018) Shantá D. Hinton   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer

(2018) Hiroki Sato et al.   CANCER SCIENCE

TPX2/Aurora kinase A signaling as a potential therapeutic target in genomically unstable cancer cells

(2018) Stephanie E. van Gijn et al.   ONCOGENE

P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition

(2017) Ahmad Najem et al.   EUROPEAN JOURNAL OF CANCER

Isotrifoliol inhibits pro-inflammatory mediators by suppression of TLR/NF-κB and TLR/MAPK signaling in LPS-induced RAW264.7 cells

(2017) Hua Li et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Dietary Intervention by Phytochemicals and Their Role in Modulating Coding and Non-Coding Genes in Cancer

(2017) Liviuta Budisan et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

5,6,7,3′,4′,5′-Hexamethoxyflavone inhibits growth of triple-negative breast cancer cells via suppression of MAPK and Akt signaling pathways and arresting cell cycle

(2017) Natasha Borah et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Dabrafenib plus trametinib in patients with BRAF V600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

(2017) Michael A Davies et al.   LANCET ONCOLOGY

Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer

(2017) Wan-xin Peng et al.   Molecular Cancer

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)

(2017) Ursula A. Germann et al.   MOLECULAR CANCER THERAPEUTICS

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas

(2017) Hezhe Lu et al.   NATURE

MEK inhibitor, PD98059, promotes breast cancer cell migration by inducing β-catenin nuclear accumulation

(2017) Ying Zhao et al.   ONCOLOGY REPORTS

Nutrigenomics in cancer: Revisiting the effects of natural compounds

(2017) Cornelia Braicu et al.   SEMINARS IN CANCER BIOLOGY

Escin induces caspase-dependent apoptosis and autophagy through the ROS/p38 MAPK signalling pathway in human osteosarcoma cells in vitro and in vivo

(2017) Jian Zhu et al.   Cell Death & Disease

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

(2017) Ryan J. Sullivan et al.   Cancer Discovery

The new era of nanotechnology, an alternative to change cancer treatment

(2017) Ancuta Jurj et al.   Drug Design Development and Therapy

Genistein inhibits the growth and regulates the migration and invasion abilities of melanoma cells via the FAK/paxillin and MAPK pathways

(2017) Shuna Cui et al.   Oncotarget

Kras and Tumor Immunity: Friend or Foe?

(2017) Jane Cullis et al.   Cold Spring Harbor Perspectives in Medicine

EGFR signaling pathways are wired differently in normal 184A1L5 human mammary epithelial and MDA-MB-231 breast cancer cells

(2017) Zachary Speth et al.   Journal of Cell Communication and Signaling

PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer

(2017) Michele Milella et al.   Scientific Reports

Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors

(2017) Concetta Di Mauro et al.   Scientific Reports

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer

(2016) C. A. Carter et al.   ANNALS OF ONCOLOGY

IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer

(2016) M. S. Caetano et al.   CANCER RESEARCH

Coumestrol Inhibits Proliferation and Migration of Prostate Cancer Cells by Regulating AKT, ERK1/2, and JNK MAPK Cell Signaling Cascades

(2016) Whasun Lim et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Inhibitory Effects of Quercetin on Progression of Human Choriocarcinoma Cells Are Mediated Through PI3K/AKT and MAPK Signal Transduction Cascades

(2016) Whasun Lim et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Apigenin Reduces Survival of Choriocarcinoma Cells by Inducing Apoptosis via the PI3K/AKT and ERK1/2 MAPK Pathways

(2016) Whasun Lim et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

(2016) David Planchard et al.   LANCET ONCOLOGY

Caffeic acid phenethyl ester activates pro-apoptotic and epithelial–mesenchymal transition-related genes in ovarian cancer cells A2780 and A2780cis

(2016) Claudia Gherman et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK

(2016) Daphne Gschwantler-Kaulich et al.   PLoS One

Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells

(2016) G Pathria et al.   Cell Death & Disease

JNK1/2 expression and modulation of STAT3 signaling in oral cancer

(2016) IOANNIS GKOUVERIS et al.   Oncology Letters

Metastatic Melanoma – A Review of Current and Future Treatment Options

(2015) E Maverakis et al.   ACTA DERMATO-VENEREOLOGICA

Novel technologies for oral squamous carcinoma biomarkers in diagnostics and prognostics

(2015) Alexandra Iulia Irimie et al.   ACTA ODONTOLOGICA SCANDINAVICA

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†

(2015) G. R. Blumenschein et al.   ANNALS OF ONCOLOGY

PIP2 and PIP3 interact with N-terminus region of TRPM4 channel

(2015) Kristyna Bousova et al.   BIOPHYSICAL CHEMISTRY

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

(2015) A. Patnaik et al.   CLINICAL CANCER RESEARCH

Expression profile of COL2A1 and the pseudogene SLC6A10P predicts tumor recurrence in high-grade serous ovarian cancer

(2015) Mahrukh K. Ganapathi et al.   INTERNATIONAL JOURNAL OF CANCER

Monitoring Ras Interactions with the Nucleotide Exchange Factor Son of Sevenless (Sos) Using Site-specific NMR Reporter Signals and Intrinsic Fluorescence

(2015) Uybach Vo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Regulation of RAF protein kinases in ERK signalling

(2015) Hugo Lavoie et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Inhibition of Survival Pathways MAPK and NF-kB Triggers Apoptosis in Pancreatic Ductal Adenocarcinoma Cells via Suppression of Autophagy

(2015) Daniela Laura Papademetrio et al.   Targeted Oncology

Phytochemicals modulate carcinogenic signaling pathways in breast and hormone-related cancers

(2015) Roxana Petric et al.   OncoTargets and Therapy

The nuclear translocation of ERK1/2 as an anticancer target

(2015) Alexander Plotnikov et al.   Nature Communications

Mutant HRAS as novel target for MEK and mTOR inhibitors

(2015) Michael K. Kiessling et al.   Oncotarget

Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway

(2015) Tingting Wang et al.   Oncotarget

Upregulation of MAPK/Erk and PI3K/Akt pathways in ulcerative colitis-associated colon cancer

(2014) Shruti Setia et al.   BIOMEDICINE & PHARMACOTHERAPY

The MAPK pathway across different malignancies: A new perspective

(2014) Mauricio Burotto et al.   CANCER

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

(2014) Anthony W. Tolcher et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

NCRNA Combined Therapy as Future Treatment Option for Cancer

(2014) Cornelia Braicu et al.   CURRENT PHARMACEUTICAL DESIGN

Featured Article: Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells

(2014) Ou Huang et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Statins and breast cancer prognosis: evidence and opportunities

(2014) Thomas P Ahern et al.   LANCET ONCOLOGY

Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration

(2014) J. Mooz et al.   Science Signaling

Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development

(2014) Elias A. El-Habr et al.   VIRCHOWS ARCHIV

p38α MAPK pathway: A key factor in colorectal cancer therapy and chemoresistance

(2014) Valentina Grossi   WORLD JOURNAL OF GASTROENTEROLOGY

p38MAPK Plays a Crucial Role in Stromal-Mediated Tumorigenesis

(2014) E. Alspach et al.   Cancer Discovery

The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNF 

(2014) M. P. Smith et al.   Cancer Discovery

Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth?

(2013) Roxana Chiorean et al.   BREAST

Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment

(2013) Ubaldo E Martinez-Outschoorn et al.   CELL CYCLE

Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors

(2013) Karen E. Sheppard et al.   EUROPEAN JOURNAL OF CANCER

p53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells

(2013) Cornelia Braicu et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

A role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis

(2013) Kantima Leelahavanichkul et al.   Molecular Oncology

Microenvironmental regulation of tumor progression and metastasis

(2013) Daniela F Quail et al.   NATURE MEDICINE

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

(2013) Jiri Polivka et al.   PHARMACOLOGY & THERAPEUTICS

BCL2A1is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition

(2013) Rizwan Haq et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors

(2012) A. B. Turke et al.   CANCER RESEARCH

Pten Loss and RAS/MAPK Activation Cooperate to Promote EMT and Metastasis Initiated from Prostate Cancer Stem/Progenitor Cells

(2012) D. J. Mulholland et al.   CANCER RESEARCH

Inside-out, outside-in, and inside–outside-in: G protein signaling in integrin-mediated cell adhesion, spreading, and retraction

(2012) Bo Shen et al.   CURRENT OPINION IN CELL BIOLOGY

Ras family of small GTPases in immunity and inflammation

(2012) Derek S Johnson et al.   CURRENT OPINION IN PHARMACOLOGY

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Approaches to Data Analyses of Clinical Trials

(2012) Curt D. Furberg et al.   PROGRESS IN CARDIOVASCULAR DISEASES

TGF-β-induced epithelial-mesenchymal transition: A link between cancer and inflammation

(2012) Jonas Fuxe et al.   SEMINARS IN CANCER BIOLOGY

Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer

(2011) Philip A. Philip et al.   CANCER

Sorafenib for advanced-stage hepatocellular carcinoma

(2011) Ciprian Tomuleasa et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Early transcriptional pattern of angiogenesis induced by EGCG treatment in cervical tumour cells

(2011) Oana Tudoran et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Opportunities and Challenges in the Development of Experimental Drug Combinations for Cancer

(2011) R. W. Humphrey et al.   JNCI-Journal of the National Cancer Institute

Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases

(2011) M. Cargnello et al.   MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS

Resistance to MEK Inhibitors: Should We Co-Target Upstream?

(2011) P. I. Poulikakos et al.   Science Signaling

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

(2011) Michelle C. Mendoza et al.   TRENDS IN BIOCHEMICAL SCIENCES

Partners in crime: the TGFβ and MAPK pathways in cancer progression

(2011) Douglas A Chapnick et al.   Cell and Bioscience

The MAPK cascades: Signaling components, nuclear roles and mechanisms of nuclear translocation

(2010) Alexander Plotnikov et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements

(2010) Shivanni Kummar et al.   NATURE REVIEWS DRUG DISCOVERY

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

(2010) E. W. Joseph et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment

(2009) Britta Weigelt et al.   BREAST CANCER RESEARCH AND TREATMENT

PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers

(2009) S. Wee et al.   CANCER RESEARCH

C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas

(2009) L. B. Jilaveanu et al.   CLINICAL CANCER RESEARCH

Spred1 and TESK1—Two New Interaction Partners of the Kinase MARKK/TAO1 That Link the Microtubule and Actin Cytoskeleton

(2008) Cindy Johne et al.   MOLECULAR BIOLOGY OF THE CELL

Mechanisms of Disease: epithelial–mesenchymal transition—does cellular plasticity fuel neoplastic progression?

(2008) Eva A Turley et al.   Nature clinical practice. Oncology